NorthWest Biotherapeutics Inc (NWBO)

[Evaluate]

ClinicalTrials.gov Identifier: NCT03014804
First received: November 30, 2016

If this trial info was first submitted to CT.gov at end November .... I wonder when NWBO is planning on putting out a PR about it?

---
# of Primary Outcome Measures = 2
# of Secondary Outcome Measures = 11 (including PFS and including Quality of Life)
# of Other Outcome Measures = 20

... Lots of measurements!


---

Estimated Enrollment: 30
Study Start Date: April 2017
Estimated Primary Completion Date: April 2019 (Final data collection date for primary outcome measure)

---

Experimental: Group I (DCVax-L)
Patients receive dendritic cell-autologous lung tumor vaccine ID on days 0, 7, 14, and weeks 4, 6, 8, 11, 14, 17 and 20.

Experimental: Group II (DCVax-L, nivolumab)
Patients receive dendritic cell-autologous lung tumor vaccine as in Group I, and nivolumab IV over 30 minutes on days 0, 14, and weeks 4, 6, 8, 11, 14, 17, and 20.

Treatment schedule looks identical between Arm 1 & Arm 2 ... with the exception of Arm 2 does not include a treatment on Day 7? Perhaps a typo?

---

Biological: Dendritic Cell-Autologous Lung Tumor Vaccine
Given ID
Other Name: DCVax-Lung

I thought DCVax-L was essentially an abbreviation for Dendritic Cell Vaccine - Lysate .... but now DCVax-L is to be recognized as DCVax-Lung?